171 related articles for article (PubMed ID: 34298646)
1. Characterization of Novel Progression Factors in Castration-Resistant Prostate Cancer Based on Global Comparative Proteome Analysis.
Na AY; Choi S; Yang E; Liu KH; Kim S; Jung HJ; Choe Y; Ha YS; Kwon TG; Lee JN; Lee S
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298646
[TBL] [Abstract][Full Text] [Related]
2. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
4. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
5. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
[TBL] [Abstract][Full Text] [Related]
6. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
7. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
[TBL] [Abstract][Full Text] [Related]
8.
Fararjeh AS; Liu YN
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
[TBL] [Abstract][Full Text] [Related]
9. A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.
Capaia M; Granata I; Guarracino M; Petretto A; Inglese E; Cattrini C; Ferrari N; Boccardo F; Barboro P
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966326
[TBL] [Abstract][Full Text] [Related]
10. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar T; Yang JC; Gao AC; Evans CP
Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
13. Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance.
Zhong S; Huang C; Chen Z; Chen Z; Luo JL
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768524
[TBL] [Abstract][Full Text] [Related]
14. The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches.
Jefferi NES; Shamhari A'; Noor Azhar NKZ; Shin JGY; Kharir NAM; Azhar MA; Hamid ZA; Budin SB; Taib IS
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979805
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.
Armandari I; Hamid AR; Verhaegh G; Schalken J
Prostate Int; 2014 Sep; 2(3):105-13. PubMed ID: 25325021
[TBL] [Abstract][Full Text] [Related]
16. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
17. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
18. Steroid hormone synthetic pathways in prostate cancer.
Mostaghel EA
Transl Androl Urol; 2013 Sep; 2(3):212-227. PubMed ID: 25379460
[TBL] [Abstract][Full Text] [Related]
19. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer.
Ishibashi Y; Tobisawa Y; Hatakeyama S; Ohashi T; Tanaka M; Narita S; Koie T; Habuchi T; Nishimura S; Ohyama C; Yoneyama T
Prostate; 2014 Nov; 74(15):1521-9. PubMed ID: 25154914
[TBL] [Abstract][Full Text] [Related]
20. Elimination of CD4
Wang C; Chen J; Zhang Q; Li W; Zhang S; Xu Y; Wang F; Zhang B; Zhang Y; Gao WQ
Cell Res; 2018 Nov; 28(11):1103-1117. PubMed ID: 30297869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
